GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lobe Sciences Ltd (XCNQ:LOBE) » Definitions » Other Income (Expense)

Lobe Sciences (XCNQ:LOBE) Other Income (Expense) : C$-2.05 Mil (TTM As of Aug. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Lobe Sciences Other Income (Expense)?

Lobe Sciences's other income expense for the Lobe Sciences's pretax income for the three months ended in Aug. 2024 was C$-2.30 Mil. Its other income expense for the trailing twelve months (TTM) ended in Aug. 2024 was C$-2.05 Mil.

Lobe Sciences Other Income (Expense) Historical Data

The historical data trend for Lobe Sciences's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lobe Sciences Other Income (Expense) Chart

Lobe Sciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Other Income (Expense)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.93 -17.47 -8.13 -1.10 -2.09

Lobe Sciences Quarterly Data
Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.06 0.01 0.01 0.23 -2.30

Lobe Sciences Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Aug. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-2.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lobe Sciences  (XCNQ:LOBE) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Lobe Sciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lobe Sciences Ltd (XCNQ:LOBE) » Definitions » Other Income (Expense)
Comparable Companies
TSXV:QPT TSXV:XRTX XCNQ:MYND TSXV:IBO TSX:APLI XCNQ:ASEP XCNQ:AWKN XCNQ:MBIO XCNQ:GTTX TSXV:MRVL VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
LOBEF:USA 6YX0:Germany
Address
1199 West Hastings Street, Suite 1400, Vancouver, BC, CAN, V6E 3T5
Website
https://www.lobesciences.com
Lobe Sciences Ltd is a biopharmaceutical company committed to discovering and developing patient-focused medicines for orphan and rare diseases. It is engaged in drug research and development to improve brain and mental health and wellness. The company plans to commercialize a medical food named Altemia for the treatment of Sickle Cell Disease and has other drugs in pipeline such as L-130 Treatment for Chronic Cluster Headache, L-131 Treatment for Pediatric Anxiety and S-100 Treatment for Sickle Cell Disease.

Lobe Sciences Headlines

No Headlines